Reuters: Health
AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.
AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer
AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer
Reuters: Health
AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.
Reuters: Health
AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment